Abstract
Subcutaneous xenografts have been used for decades to study hepatocellular carcinoma (HCC). These models do not reproduce the specific pathophysiological features of HCCs, which occur in cirrhotic livers that show pronounced necroinflammation, abnormal angiogenesis and extensive fibrosis. As these features are crucial for studying the role of the pathologic host microenvironment in tumor initiation, progression and treatment response, alternative HCC models are desirable. Here we describe a syngeneic orthotopic HCC model in immunocompetent mice with liver cirrhosis induced by carbon tetrachloride (CCl4) that recapitulates key features of human HCC. Induction of substantial hepatic fibrosis requires 12 weeks of CCl4 administration. Intrahepatic implantation of mouse HCC cell lines requires 30 min per mouse. Tumor growth varies by tumor cell line and mouse strain used. Alternatively, tumors can be induced in a genetically engineered mouse model. In this setting, CCl4 is administered for 12 weeks after tail-vein injection of Cre-expressing adenovirus (adeno-Cre) in Stk4−/−Stk3F/− (also known as Mst1−/−Mst2F/−; F indicates a floxed allele) mice, and it results in the development of HCC tumors (hepatocarcinogenesis) concomitantly with liver cirrhosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Njei, B., Rotman, Y., Ditah, I. & Lim, J.K. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 61, 191–199 (2015).
Forner, A. & Bruix, J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 13, 750–751 (2012).
Zhu, A.X., Duda, D.G., Sahani, D.V. & Jain, R.K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8, 292–301 (2011).
Hernandez-Gea, V., Toffanin, S., Friedman, S.L. & Llovet, J.M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144, 512–527 (2013).
Chauhan, V.P., Stylianopoulos, T., Boucher, Y. & Jain, R.K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281–298 (2011).
Inghilesi, A.L. et al. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J. Gastroenterol. 20, 786–794 (2014).
Chen, Y. et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 α/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59, 1435–1447 (2014).
Forner, A., Reig, M.E., de Lope, C.R. & Bruix, J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 30, 61–74 (2010).
European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
Fukumura, D. & Jain, R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 101, 937–949 (2007).
Chen, Y. et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61, 1591–1602 (2015).
Newell, P., Villanueva, A., Friedman, S.L., Koike, K. & Llovet, J.M. Experimental models of hepatocellular carcinoma. J. Hepatol. 48, 858–879 (2008).
Huynh, H., Soo, K.C., Chow, P.K., Panasci, L. & Tran, E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin. Cancer Res. 12, 4306–4314 (2006).
Coulouarn, C. et al. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 44, 1003–1011 (2006).
Srivastava, J. et al. Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology 56, 1782–1791 (2012).
Srivastava, J. et al. Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology 61, 915–929 (2015).
Stauffer, J.K. et al. Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res. 71, 2718–2727 (2011).
Willimsky, G., Schmidt, K., Loddenkemper, C., Gellermann, J. & Blankenstein, T. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J. Clin. Invest. 123, 1032–1043 (2013).
Wolf, M.J. et al. Metabolic activation of intrahepatic CD8+ T cells and NK T cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26, 549–564 (2014).
Zhou, D. et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425–438 (2009).
Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253–1267 (2006).
Xu, M.Z. et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30, 1229–1240 (2011).
Hato, T., Goyal, L., Greten, T.F., Duda, D.G. & Zhu, A.X. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 60, 1776–1782 (2014).
Zhang, H.L. et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J. Hepatol. 57, 803–812 (2012).
Yin, H. et al. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver. Gastroenterology 146, 801–811 (2014).
Lu, L. et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. USA 107, 1437–1442 (2010).
Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals http://www.nap.edu/catalog/12910/guide-for-the-care-and-use-of-laboratory-animals-eighth (National Academies Press, 2011).
The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20, 15–20 (1994).
Lee, K.H. et al. Percutaneous US-guided implantation of Vx-2 carcinoma into rabbit liver: a comparison with open surgical method. J. Surg. Res. 155, 94–99 (2009).
Bissig, K.D., Le, T.T., Woods, N.B. & Verma, I.M. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl. Acad. Sci. USA 104, 20507–20511 (2007).
Tannous, B.A. & Teng, J. Secreted blood reporters: insights and applications. Biotechnol. Adv. 29, 997–1003 (2011).
Acknowledgements
The authors thank D. Nguyen, A. Pieters and C. Smith for their outstanding support in establishing this protocol. This study was supported by the NIH grant P01-CA080124, and in part by grants R01-CA159258, R21-CA139168, R01-CA126642 and National Cancer Institute/Proton Beam Federal Share Program awards (to D.G.D. and R.K.J.); by the American Cancer Society grant 120733-RSG-11-073-01-TBG (to D.G.D.); by a Max Kade Fellowship by the Austrian Academy of Science and a Erwin-Schroedinger Fellowship by the Austrian Science Funds (to T.R.); by a Howard Hughes Medical Institute Medical Research Fellowship (to C.F.); and by a Postdoctoral Fellowship from Astellas Foundation for Research on Metabolic Disorders (to T.H.).
Author information
Authors and Affiliations
Contributions
T.R., Y.C., A.X.Z., R.K.J. and D.G.D. contributed to the concept and design of the study. T.R., Y.C., R.R.R., T.H., P.H., S.R., C.F., R.S. and G.Y.L. were responsible for acquisition of the data. T.R., Y.C., R.R.R., T.H., R.S., P.H., G.Y.L., A.X.Z., N.B., R.K.J. and D.G.D. contributed to analysis and interpretation of the data. T.R., Y.C., R.R.R., T.H., C.F., R.S., S.R., P.H., G.Y.L., A.X.Z., N.B., R.K.J. and D.G.D. were involved in drafting of the article and revising it for important intellectual content.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Imaging of orthotopic hepatocellular carcinoma by using abdominal high-frequency ultrasound.
(A) B-mode image of a HCA-1 Tumor 10 days after orthotopic implantation in a cirrhotic C3H mouse. Scale bar: 2mm. (B) B-mode image of a HCC tumor developed 10 weeks after Adeno-Cre injection and CCl4 administration in a Mst1−/−Mst2F/− mouse. Scale bar: 2mm.
Supplementary information
Supplementary Text and Figures
Supplementary Figure 1 (PDF 1450 kb)
Rights and permissions
About this article
Cite this article
Reiberger, T., Chen, Y., Ramjiawan, R. et al. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc 10, 1264–1274 (2015). https://doi.org/10.1038/nprot.2015.080
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2015.080